Categories
Archives
- 2026
- 2025
- 2024
- 2023
Mar
04
CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome or Lennox-Gastaut Syndrome
Feb
27
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
Feb
25
Shining a Light on Resilience: Honoring Black History Month and Raising Awareness for Epilepsy
Feb
12
Providing U.S. Policy Actions on Rare Disease
Feb
03
Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented
Jan
31
Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape
Jan
16
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
Dec
18
Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions
Dec
06
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting